1. Home
  2. ZURA vs PDLB Comparison

ZURA vs PDLB Comparison

Compare ZURA & PDLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.45

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Ponce Financial Group Inc.

PDLB

Ponce Financial Group Inc.

HOLD

Current Price

$20.30

Market Cap

481.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
PDLB
Founded
2022
1960
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
481.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ZURA
PDLB
Price
$4.45
$20.30
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
1.7M
63.0K
Earning Date
05-14-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
160.87
EPS
N/A
0.71
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$28.58
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$13.91
52 Week High
$7.25
$21.10

Technical Indicators

Market Signals
Indicator
ZURA
PDLB
Relative Strength Index (RSI) 30.44 49.27
Support Level $4.22 $19.66
Resistance Level $5.94 $20.81
Average True Range (ATR) 0.37 0.38
MACD -0.17 -0.02
Stochastic Oscillator 4.03 47.83

Price Performance

Historical Comparison
ZURA
PDLB

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About PDLB Ponce Financial Group Inc.

Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.

Share on Social Networks: